ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer von Tarantino, P., Viale, G., Press, M.F., Hu, X., Penault-Llorca, F., Bardia, A., Batistatou, A., Burstein, H.J., Carey, L.A., Cortes, J., Denkert, C., Diéras, V., Jacot, W., Koutras, A.K., Lebeau, A., Loibl, S., Modi, S., Mosele, M.F., Provenzano, E., Pruneri, G., Reis-Filho, J.S., Rojo, F., Salgado, R., Schmid, P., Schnitt, S.J., Tolaney, S.M., Trapani, D., Vincent-Salomon, A., Wolff, A.C., Pentheroudakis, G., André, F., Curigliano, G.

Volltext

Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group von Mosele, M.F., Westphalen, C.B., Stenzinger, A., Barlesi, F., Bayle, A., Bièche, I., Bonastre, J., Castro, E., Dienstmann, R., Krämer, A., Czarnecka, A.M., Meric-Bernstam, F., Michiels, S., Miller, R., Normanno, N., Reis-Filho, J., Remon, J., Robson, M., Rouleau, E., Scarpa, A., Serrano, C., Mateo, J., André, F.

Volltext

230TiP Exploring mechanisms of action and resistance in innovate cancer therapies: The UNLOCK program von Alonso de Castro, B., Rodriguez, J.E., Mosele, M.F., Nicotra, C., Camus, M. Ngo, Scoazec, J., Vasseur, D., Bigot, L., Nikolaev, S., Wang, J., Gerome, J-C., Brayé, F., André, F., Aix, S. Ponce, Massard, C.P., Italiano, A., Loriot, Y., Friboulet, L.

Volltext

Precision oncology in patients with breast cancer: towards a ‘screen and characterize’ approach von Rassy, E., Mosele, M.F., Di Meglio, A., Pistilli, B., Andre, F.

Volltext

343MO Unraveling the mechanisms of action and resistance to trastuzumab deruxtecan (T-DXd): Supplementary biomarker analyses from DAISY trial von Mosele, M.F., Lusque, A., Dieras, V.C., Deluche, E., Ducoulombier, A., Pistilli, B., Bachelot, T., Viret, F., Levy, C., Pradat, Y.C., Signolle, N., Le Bescond, L., Tran, D., Droin, N., Kobayashi, M., Kakewaga, T., Deloger, M., Jimenez, M., Lacroix-Triki, M., André, F.

Volltext

340O Efficacy, safety and biomarker analysis of ICARUS-BREAST01: A phase II study of patritumab deruxtecan (HER3-DXd) in patients (pts) with HR+/HER2- advanced breast cancer (ABC) von Pistilli, B., Pierotti, L., Lacroix-Triki, M., Vicier, C., Frenel, J-S., D'Hondt, V., Dalenc, F., Bachelot, T., Ducoulombier, A., Benderra, M-A., Loirat, D., Mayeur, D., Nachabeh, G.B., Sporchia, A., Suto, F., Michiels, S., Corcos, N., Mosele, M.F., André, F., Montagnac, G.

Volltext

LBA72 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial von Mosele, M.F., Lusque, A., Dieras, V.C., Deluche, E., Ducoulombier, A., Pistilli, B., Bachelot, T., Viret, F., Levy, C., Pradat, Y.C., Tran, D.T.N., Droin, N., Kobayashi, M., Kakewaga, T., Deloger, M., Job, B., Jimenez, M., Lacroix-Triki, M., André, F.

Volltext

260P Antitumor activity of trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer (mBC) and brain metastases (BMs) from DAISY trial von Epaillard, N., Lusque, A., Pistilli, B., André, F., Bachelot, T., Pierga, J-Y., Ducoulombier, A., Jouannaud, C., Viret, F., Salabert, L., Johnson, A.C., Deluche, E., Durando, X., Petit, T., Filleron, T., Mahier Ait Oukhatar, C., Dieras, V.C., Mosele, M.F.

Volltext

LBA1 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial von Mosele, M.F., Lusque, A., Dieras, V., Deluche, E., Ducoulombier, A., Pistilli, B., Bachelot, T., Viret, F., Levy, C., Signolle, N., Tran, D., Garberis, I.J., Le-Bescond, L., Dien, A. Tran, Droin, N., Kobayashi, M., Kakegawa, T., Jimenez, M., Lacroix-Triki, M., André, F.

Volltext

Outcome and mutational landscape of patients with PIK3CA-mutated metastatic breast cancer (mBC) von Mosele, M.F., Lusque, A., Tran Dien, A., Droin, N., Le Tourneau, C., Lacroix, L., Bieche, I., Massard, C., Bertucci, F., André, F.

Volltext

52P Comparing the genomic landscape of de novo vs recurrent metastatic breast cancer by ctDNA and tissue profiling von Giugliano, F., Douglas, J.R. Dixon, Dien, A. Tran, Pagliuca, M., Minot, L., Rouleau, E., Bayle, A., Curigliano, G., Verret, B., Viansone, A.A., Mosele, M.F., Pistilli, B., André, F., Italiano, A., Mourato, J.T.L. Ribeiro

Volltext

155TiP Exploring mechanisms of action and resistance to innovative therapeutic drugs: UNLOCK program von Rodriguez, J.E., Alonso de Castro, B., Mosele, M.F., Nicotra, C., Camus, M. Ngo, Halimi, A., Natali, E., Scoazec, J-Y., Vasseur, D., Bigot, L., Nikolaev, S., Wang, J., Gerome, J-C., Aix, S. Ponce, Massard, C., André, F., Italiano, A., Friboulet, L., Loriot, Y.

Volltext

29P Prevalence of high tumor mutational burden (TMB) in patients with metastatic breast cancer (mBC) assessed by liquid biopsy (LB) von Ribeiro, J.T.M.L.M., Dien, A. Tran, Mignot, L., Pagliuca, M., Rassy, E., Mosele, M.F., Grinda, T., Viansone, A.A., Géraud, A., Verret, B., Bayle, A., Pistilli, B., André, F., Italiano, A.

Volltext

7P Trastuzumab deruxtecan (T-DXd) for advanced breast cancer (ABC) patients (pts), regardless of HER2 status: A phase II study with biomarkers analysis (DAISY) - update analysis wi... von Dieras, V.C., André, F., Lusque, A., Pistilli, B., Bachelot, T., Pierga, J-Y., Viret, F., Levy, C., Salabert, L., Dalenc, F., Jouannaud, C., Fournel, P., Durando, X., Petit, T., Ait Oukhatar, C. Mahier, Filleron, T., Mosele, M.F., Lacroix-Triki, M., Ducoulombier, A., Deluche, E.

Volltext

189O A phase II study of patritumab deruxtecan (HER3-DXd), in patients (pts) with advanced breast cancer (ABC), with biomarker analysis to characterize response to therapy (ICARUS-... von Pistilli, B., Ibrahimi, N., Lacroix-Triki, M., D'Hondt, V., Vicier, C., Frenel, J-S., Dalenc, F., Bachelot, T., Benderra, M-A., Loirat, D., Ducoulombier, A., Mayeur, D., Nachabeh, G.B., Serhal, K., Corcos, N., Sellami, D., Michiels, S., André, F., Mosele, M.F., Montagnac, G.

Volltext